Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

E.S. Newlands; M. F. G. STEVENS; Stephen R. Wedge; Richard T. Wheelhouse; C. Brock

doi:10.1016/s0305-7372(97)90019-0

Keywords

MedicineTemozolomideClinical trialMedical physicsOncologyInternal medicineIntensive care medicineChemotherapy

MeSH Terms

AdultAnimalsAntineoplastic AgentsAlkylatingClinical TrialsPhase I as TopicClinical TrialsPhase II as TopicDacarbazineFemaleHumansMaleMiddle AgedNeoplasmsExperimentalTemozolomideTumor CellsCultured

Affiliated Institutions

Related Publications

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

PURPOSE The primary objective was to determine clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast...

1996 Journal of Clinical Oncology 352 citations

Hereditary Colorectal Cancer

Henry T. Lynch , Albert de la Chapelle

The question, "Is cancer hereditary?" has been answered beyond any doubt through the discovery of germ-line cancer-causing mutations in a subset of colorectal cancers (CRCs). Cl...

2003 New England Journal of Medicine 2165 citations

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

Keunchil Park , Kōichi Goto

In the majority of these reports, objective response rates of > 25% and disease control rates of > 60% have been described. Treatment with gefitinib resulted in a median time to...

2006 Current Medical Research and Opinion 92 citations

Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma

Valérie Boige , David Malka , Abderrahmane Bourredjem +9 more

Abstract Objective. Hepatocellular carcinoma (HCC) is a highly vascularized tumor in which neoangiogenesis contributes to growth and metastasis. We assessed the safety, efficacy...

2012 The Oncologist 131 citations

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman , Sara Lonardi , Francesco Leone +16 more

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair...

2017 Journal of Clinical Oncology 69 citations

Publication Info

Year: 1997
Type: review
Volume: 23
Issue: 1
Pages: 35-61
Citations: 797
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

797

OpenAlex

Influential

655

CrossRef

Cite This

APA Style

                            
                                
                                    E.S. Newlands, 
                                
                                    M. F. G. STEVENS, 
                                
                                    Stephen R. Wedge
                                
                                et al.
                            
                            (1997). 
                            Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. 
                            Cancer Treatment Reviews
                            , 23
                            (1)
                            , 35-61.
                            https://doi.org/10.1016/s0305-7372(97)90019-0
                        

Identifiers

DOI: 10.1016/s0305-7372(97)90019-0
PMID: 9189180

Data Quality

Data completeness: 68%